Ovid Therapeutics Inc. 8-K

What Happened

• Ovid Therapeutics (OVID) filed an 8-K on June 11, 2026 reporting the results of its annual meeting held June 10, 2026. As of the April 15, 2026 record date there were 173,037,131 shares outstanding; 130,958,928 shares (75.7%) were present or represented by proxy, constituting a quorum. Jeremy M. Levin, DPhil, MB BChir was elected to a three-year term as director.

Key Details

• Shares outstanding (record date April 15, 2026): 173,037,131; shares present/represented: 130,958,928 (75.7%).
• Director election (Jeremy M. Levin): For 87,219,707; Withheld 8,528,008; Broker non-votes 35,211,213.
• Advisory vote on named executive officer compensation ("say-on-pay"): For 84,511,953; Against 8,901,691; Abstain 2,334,071; Broker non-votes 35,211,213.
• Ratification of independent auditor (KPMG LLP) for fiscal 2026: For 130,845,667; Against 32,505; Abstain 80,756.

Why It Matters

• These voting outcomes confirm board continuity (Levin elected) and shareholder support for the company’s executive compensation program and choice of auditor, which can affect governance perceptions and ongoing investor confidence. The filing is procedural disclosure of the vote totals and does not announce operational or financial results.